CN112203685A - 使用结合白细胞介素-17a(il-17a)的抗体的自身免疫紊乱和炎性紊乱的治疗 - Google Patents

使用结合白细胞介素-17a(il-17a)的抗体的自身免疫紊乱和炎性紊乱的治疗 Download PDF

Info

Publication number
CN112203685A
CN112203685A CN201980036330.7A CN201980036330A CN112203685A CN 112203685 A CN112203685 A CN 112203685A CN 201980036330 A CN201980036330 A CN 201980036330A CN 112203685 A CN112203685 A CN 112203685A
Authority
CN
China
Prior art keywords
sequence
seq
antibody
light chain
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980036330.7A
Other languages
English (en)
Chinese (zh)
Inventor
弗兰克·J·卡尔佐内
方美
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Remd Biotherapeutics Inc
Original Assignee
Remd Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remd Biotherapeutics Inc filed Critical Remd Biotherapeutics Inc
Publication of CN112203685A publication Critical patent/CN112203685A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980036330.7A 2018-03-29 2019-03-29 使用结合白细胞介素-17a(il-17a)的抗体的自身免疫紊乱和炎性紊乱的治疗 Pending CN112203685A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862649854P 2018-03-29 2018-03-29
US62/649,854 2018-03-29
PCT/US2019/024794 WO2019191563A1 (en) 2018-03-29 2019-03-29 Treatment of autoimmune and inflammatory disorders using antibodies that bind interleukin-17a (il-17a)

Publications (1)

Publication Number Publication Date
CN112203685A true CN112203685A (zh) 2021-01-08

Family

ID=68058546

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980036330.7A Pending CN112203685A (zh) 2018-03-29 2019-03-29 使用结合白细胞介素-17a(il-17a)的抗体的自身免疫紊乱和炎性紊乱的治疗

Country Status (5)

Country Link
US (1) US20210079087A1 (https=)
EP (1) EP3773717A4 (https=)
JP (1) JP2021519589A (https=)
CN (1) CN112203685A (https=)
WO (1) WO2019191563A1 (https=)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1407993A (zh) * 2000-03-03 2003-04-02 协和发酵工业株式会社 基因重组抗体及其抗体片段
US20040005615A1 (en) * 2002-05-24 2004-01-08 Jing Li Amplification and overexpression of oncogenes
AU2005268857A1 (en) * 2004-08-05 2006-02-09 Novartis Ag IL-17 antagonistic antibodies
US20060251668A1 (en) * 2002-11-29 2006-11-09 Steffen Goletz Tumor-specific recognition molecules
US20080095775A1 (en) * 2006-06-13 2008-04-24 Lewis Katherine E Il-17 and il-23 antagonists and methods of using the same
CN101611057B (zh) * 2006-06-23 2013-03-20 阿斯特拉捷利康股份公司 人il-17的抗体分子
CN101646690B (zh) * 2006-08-11 2013-10-23 默沙东公司 抗il-17a抗体
US20160039948A1 (en) * 2013-03-15 2016-02-11 Amgen Research (Munich) Gmbh Antibody constructs for influenza m2 and cd3

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011053763A2 (en) * 2009-10-30 2011-05-05 Centocor Ortho Biotech Inc. Il-17a antagonists
LT2953969T (lt) * 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1407993A (zh) * 2000-03-03 2003-04-02 协和发酵工业株式会社 基因重组抗体及其抗体片段
US20040005615A1 (en) * 2002-05-24 2004-01-08 Jing Li Amplification and overexpression of oncogenes
US20060251668A1 (en) * 2002-11-29 2006-11-09 Steffen Goletz Tumor-specific recognition molecules
AU2005268857A1 (en) * 2004-08-05 2006-02-09 Novartis Ag IL-17 antagonistic antibodies
US20080095775A1 (en) * 2006-06-13 2008-04-24 Lewis Katherine E Il-17 and il-23 antagonists and methods of using the same
CN101611057B (zh) * 2006-06-23 2013-03-20 阿斯特拉捷利康股份公司 人il-17的抗体分子
CN101646690B (zh) * 2006-08-11 2013-10-23 默沙东公司 抗il-17a抗体
US20160039948A1 (en) * 2013-03-15 2016-02-11 Amgen Research (Munich) Gmbh Antibody constructs for influenza m2 and cd3

Also Published As

Publication number Publication date
JP2021519589A (ja) 2021-08-12
EP3773717A4 (en) 2022-05-11
US20210079087A1 (en) 2021-03-18
WO2019191563A1 (en) 2019-10-03
EP3773717A1 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
US11319372B2 (en) Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CTLA-4)
US11332531B2 (en) Immunotherapy using antibodies that bind programmed death ligand-1 (PD-L1)
CN101522716A (zh) 抗人il-4受体的高亲和力人抗体
US11248049B2 (en) Immunotherapy using antibodies that bind Programmed Death 1 (PD-1)
US11242398B2 (en) Anti-OX40 antibodies and methods of activating OX40
US20230151104A1 (en) Chemokine receptor 4 (cxcr4) antagonist antibodies
US20260109770A1 (en) C-c chemokine receptor type 8 (ccr8) antagonist antibodies
KR102356187B1 (ko) 항-gm-csf 항체 및 이것의 사용
US11629184B2 (en) Calcitonin gene-related peptide (CGRP) antagonist antibodies
CN115803062B (zh) 滋养层细胞表面抗原2(trop-2)抗体
CN112203685A (zh) 使用结合白细胞介素-17a(il-17a)的抗体的自身免疫紊乱和炎性紊乱的治疗

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210108